These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 20824430)
1. Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model. Pinkhasov J; Alvarez ML; Pathangey LB; Tinder TL; Mason HS; Walmsley AM; Gendler SJ; Mukherjee P Cancer Immunol Immunother; 2010 Dec; 59(12):1801-11. PubMed ID: 20824430 [TBL] [Abstract][Full Text] [Related]
2. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice. Nyström-Asklin J; Adamsson J; Harandi AM Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617 [TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit. Lu W; Qiu L; Yan Z; Lin Z; Cao M; Hu C; Wang Z; Wang J; Yu Y; Cheng X; Cao P; Li R Oncotarget; 2015 Oct; 6(33):34537-48. PubMed ID: 26417929 [TBL] [Abstract][Full Text] [Related]
4. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. Adamsson J; Lindblad M; Lundqvist A; Kelly D; Holmgren J; Harandi AM J Immunol; 2006 Apr; 176(8):4902-13. PubMed ID: 16585586 [TBL] [Abstract][Full Text] [Related]
6. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Cheng C; Bettahi I; Cruz-Fisher MI; Pal S; Jain P; Jia Z; Holmgren J; Harandi AM; de la Maza LM Vaccine; 2009 Oct; 27(44):6239-46. PubMed ID: 19686693 [TBL] [Abstract][Full Text] [Related]
7. Immunization with cholera toxin B subunit induces high-level protection in the suckling mouse model of cholera. Price GA; McFann K; Holmes RK PLoS One; 2013; 8(2):e57269. PubMed ID: 23468950 [TBL] [Abstract][Full Text] [Related]
8. The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes. Bregenholt S; Wang M; Wolfe T; Hughes A; Baerentzen L; Dyrberg T; von Herrath MG; Petersen JS Scand J Immunol; 2003 May; 57(5):432-8. PubMed ID: 12753499 [TBL] [Abstract][Full Text] [Related]
9. Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. Rask C; Holmgren J; Fredriksson M; Lindblad M; Nordström I; Sun JB; Czerkinsky C Clin Exp Allergy; 2000 Jul; 30(7):1024-32. PubMed ID: 10848926 [TBL] [Abstract][Full Text] [Related]
10. Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit. Rhie GE; Jung HM; Kim BS; Mekalanos JJ Vaccine; 2008 Oct; 26(43):5443-8. PubMed ID: 18582519 [TBL] [Abstract][Full Text] [Related]
11. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. Sun JB; Flach CF; Czerkinsky C; Holmgren J J Immunol; 2008 Dec; 181(12):8278-87. PubMed ID: 19050244 [TBL] [Abstract][Full Text] [Related]
12. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723 [TBL] [Abstract][Full Text] [Related]
13. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556 [TBL] [Abstract][Full Text] [Related]
14. Important role for FcγRIIB on B lymphocytes for mucosal antigen-induced tolerance and Foxp3+ regulatory T cells. Sun JB; Xiang Z; Smith KG; Holmgren J J Immunol; 2013 Oct; 191(8):4412-22. PubMed ID: 24038083 [TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory sequence oligdeoxynucleotide/cholera toxin B conjugate: a novel allergen-independent intranasal vaccine for allergic rhinitis. Won TB; Quan SH; Kim DY; Rhee CS; Lee CH Ann Allergy Asthma Immunol; 2009 Apr; 102(4):314-22. PubMed ID: 19441603 [TBL] [Abstract][Full Text] [Related]
16. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429 [TBL] [Abstract][Full Text] [Related]
17. Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells. George Chandy A; Hultkrantz S; Raghavan S; Czerkinsky C; Lebens M; Telemo E; Holmgren J Immunology; 2006 Jul; 118(3):311-20. PubMed ID: 16827892 [TBL] [Abstract][Full Text] [Related]
18. Enhanced immunological tolerance against allograft rejection by oral administration of allogeneic antigen linked to cholera toxin B subunit. Sun JB; Li BL; Czerkinsky C; Holmgren J Clin Immunol; 2000 Nov; 97(2):130-9. PubMed ID: 11027453 [TBL] [Abstract][Full Text] [Related]
19. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Lei H; Peng X; Jiao H; Zhao D; Ouyang J Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406 [TBL] [Abstract][Full Text] [Related]
20. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Blanchard TG; Lycke N; Czinn SJ; Nedrud JG Immunology; 1998 May; 94(1):22-7. PubMed ID: 9708182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]